Logo
x

Search

Subscribe Now

Pulmonary Arterial Hypertension

United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021

United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension a...

  • September 8, 2021
Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021

Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary...

  • August 31, 2021
Janssen's Uptravi (selexipag) Receives the US FDA's Approval for IV Use in Adults with Pulmonary Arterial Hypertension

Janssen's Uptravi (selexipag) Receives the US FDA's Approval for IV Use in Adults with Pulmonary Arterial Hypertension

  • August 2, 2021
Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

  • April 22, 2021
Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension- Published in NEJM

Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension- Published in...

  • April 2, 2021
Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension

Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension

  • October 1, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.